You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 26, 2024

Details for New Drug Application (NDA): 213150


✉ Email this page to a colleague

« Back to Dashboard


NDA 213150 describes FENSOLVI KIT, which is a drug marketed by Tolmar and is included in one NDA. It is available from one supplier. There are two patents protecting this drug. Additional details are available on the FENSOLVI KIT profile page.

The generic ingredient in FENSOLVI KIT is leuprolide acetate. There are twenty-two drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the leuprolide acetate profile page.
Summary for 213150
Tradename:FENSOLVI KIT
Applicant:Tolmar
Ingredient:leuprolide acetate
Patents:2
Pharmacology for NDA: 213150
Medical Subject Heading (MeSH) Categories for 213150
Suppliers and Packaging for NDA: 213150
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
FENSOLVI KIT leuprolide acetate POWDER;SUBCUTANEOUS 213150 NDA TOLMAR Inc. 62935-153 62935-153-50 1 KIT in 1 CARTON (62935-153-50) * .375 mL in 1 SYRINGE (62935-154-50) * .375 mL in 1 SYRINGE (62935-155-40)
FENSOLVI KIT leuprolide acetate POWDER;SUBCUTANEOUS 213150 NDA TOLMAR Inc. 62935-163 62935-163-60 1 SYRINGE in 1 CARTON (62935-163-60) / .375 mL in 1 SYRINGE

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:POWDER;SUBCUTANEOUSStrength45MG
Approval Date:May 1, 2020TE:RLD:Yes
Patent:11,771,841Patent Expiration:Dec 22, 2041Product Flag?YSubstance Flag?YDelist Request?
Patent:11,931,559Patent Expiration:Dec 22, 2041Product Flag?Substance Flag?YDelist Request?

Expired US Patents for NDA 213150

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Tolmar FENSOLVI KIT leuprolide acetate POWDER;SUBCUTANEOUS 213150-001 May 1, 2020 8,470,359 ⤷  Subscribe
Tolmar FENSOLVI KIT leuprolide acetate POWDER;SUBCUTANEOUS 213150-001 May 1, 2020 9,539,333 ⤷  Subscribe
Tolmar FENSOLVI KIT leuprolide acetate POWDER;SUBCUTANEOUS 213150-001 May 1, 2020 9,914,802 ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.